WO2007072749A1 - 鎮咳剤 - Google Patents
鎮咳剤 Download PDFInfo
- Publication number
- WO2007072749A1 WO2007072749A1 PCT/JP2006/325023 JP2006325023W WO2007072749A1 WO 2007072749 A1 WO2007072749 A1 WO 2007072749A1 JP 2006325023 W JP2006325023 W JP 2006325023W WO 2007072749 A1 WO2007072749 A1 WO 2007072749A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- carbon atoms
- cpm
- carbons
- hydrogen
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
- C07D489/08—Oxygen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
Definitions
- the present invention relates to an antitussive agent comprising, as an active ingredient, a morphinan derivative having a nitrogen-containing cyclic substituent or a pharmacologically acceptable acid addition salt thereof useful for the treatment or prevention of cough.
- Antitussives are widely used for the treatment of cough associated with respiratory diseases such as common cold (cold syndrome), bronchitis, and pneumonia, and are classified into central antitussives acting on the cough center and peripheral antitussives. be able to. Most drugs currently in use are central, and central antitussives are further classified into non-narcotic and narcotic.
- tipepidine hibenzate, dextromethorphan hydrobromide, etc. are often used, but it may cause drowsiness, dizziness, headache, etc. due to the action outside the cough center. In general, the action is weaker than that of narcotic antitussives, and the antitussive effect may not be obtained sufficiently.
- codine phosphate As a narcotic antitussive agent, codine phosphate, dihydrocodine phosphate, etc. are widely used. Resistance, dependency formation and abuse are also problems.
- codin phosphate, dihydrocodine phosphate also has a morphinan skeleton, and its 6-position is substituted with a hydroxyl group, which is different from the compound having a nitrogen-containing cyclic substituent at the 6-position.
- morphinan compounds having a nitrogen-containing cyclic substituent at the 6-position it has already been suggested that the cyclic anamino-substituted compound has an antitussive effect (Patent Documents 1, 2, and 3).
- some morphinan compounds having a cyclic imide group at the 6-position have a chemical structure disclosed although they are not directly shown to have an antitussive action. (Non-patent documents 1, 2, 3).
- the compound of the present invention has a therapeutic effect on pollakiuria (urinary incontinence) (Patent Document 4), an epilepsy therapeutic effect (Patent Document 5), and a therapeutic effect on pain (Patent Document 6). ) Is disclosed (however, for the treatment of pain, this application Published after the priority date).
- Patent Document 1 Japanese Patent Publication No. 41-18824
- Patent Document 2 Japanese Patent Publication No. 41-18826
- Patent Document 3 International Publication No. 95/03308 Pamphlet
- Patent Document 4 Pamphlet of International Publication No. 2004/033457 (European Patent Office Publication EP1555266)
- Patent Document 5 Pamphlet of International Publication No. 2005/094826
- Patent Document 6 International Publication No. 2006/049248 Pamphlet
- Non-Patent Document 1 Simon C. et.al, Tetrahedron, 50, 9757-9768, 1994.
- Non-Patent Document 2 Sayre L.M. et.al., J.Med.Chem., 27, 1325-1335, 1984.
- Non-Patent Document 3 Simon C. et.al, Synth.Commun., 22, 913-921, 1992.
- An object of the present invention is to provide a cough suppressant containing, as an active ingredient, a morphinan derivative having a nitrogen-containing cyclic substituent or a pharmacologically acceptable acid addition salt thereof useful for treating or preventing cough.
- R 1 is hydrogen, alkyl having 1 to 5 carbon atoms, cycloalkyl alkyl having 4 to 7 carbon atoms, cycloalkyl alkyl having 5 to 8 carbon atoms, aryl having 6 to 12 carbon atoms, or 7 carbon atoms. 13 aralkyls, 3 to 7 carbons, fulleralkyls (alkyls with 1 to 5 carbons), chenilalkyls (alkyls with 1 to 5 carbons), or pyridylalkyls (alkyls) Represents a carbon number of 1 to 5);
- R 2 and R 3 are each independently hydrogen, hydroxy, alkoxy having 1 to 5 carbon atoms, alkoxy having 3 to 7 carbon atoms, aralkyloxy having 7 to 13 carbon atoms, or an alkanoyl having 1 to 5 carbon atoms. Represents ruoxy;
- -X- is an alkylene, alkylene, or alkylene having 2 to 7 carbon atoms that forms part of the cyclic structure, but one or more carbon atoms are replaced by nitrogen, oxygen, or sulfur atoms. Represents);
- R 4 represents hydrogen or alkyl having 1 to 5 carbons
- k represents an integer from 1 to 8;
- R 6 is each independently fluorine, chlorine, bromine, iodine, nitro, alkyl having 1 to 5 carbons, aralkyl having 7 to 13 carbons, trifluoromethyl, trifluoromethoxy, or carbon containing 6 to 12 carbons.
- p represents an integer from 0 to 5;
- Each R 9 is independently hydrogen, alkyl having 1 to 5 carbons, alkenyl having 3 to 7 carbons, aryl having 6 to 12 carbons, or aralkyl having 7 to 13 carbons;
- R 1Q is hydrogen Represents an alkyl having 1 to 5 carbon atoms, an alkyl having 2 to 5 carbon atoms, an aralkyl having 7 to 13 carbon atoms, (CH R 7 (p, R 7 is as defined above);
- R u and R 12 are bonded to each other to represent -0-, -S- or -CH-, or R 11 is hydrogen and R 12 is hydrogen.
- R 13 and R 14 together represent oxo, or R 13 is hydrogen, R 14 is hydrogen, hydroxy, alkoxy having 1 to 5 carbons, or alkanoyl having 1 to 5 carbons.
- General formula (I) includes (+) body, (one) body, (shi) body. Or a pharmaceutically acceptable acid addition salt thereof as an active ingredient.
- An antitussive agent is provided.
- the present invention also provides use of the above morphinan derivative having a nitrogen-containing cyclic substituent or a pharmacologically acceptable acid addition salt thereof for producing an antitussive.
- the present invention provides a cough-suppressing method comprising administering to a patient an effective amount of the morphinan derivative having the nitrogen-containing cyclic substituent or a pharmacologically acceptable acid addition salt thereof.
- the antitussive agent of the present invention has an excellent cough treatment or prevention effect and has few side effects.
- the antitussive of the present invention contains, as an active ingredient, a morphinan derivative having a nitrogen-containing cyclic substituent represented by the general formula (I) or a pharmacologically acceptable acid addition salt thereof. To do.
- R 13 and R 14 are preferably oxo together or R 13 is hydrogen and R 14 is hydrogen or hydroxy, particularly R. 13 and R 14 are preferably hydrogen, ie, unsubstituted.
- R 1 is preferably hydrogen, a cycloalkylalkyl having 4 to 7 carbon atoms, a cycloalkenyl alkyl having 6 to 8 carbon atoms, an aryl having 6 to 12 carbon atoms, or an alcohol having 3 to 7 carbon atoms.
- hydrogen, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, aryl, and prenyl particularly hydrogen, cyclopropylmethyl, cyclobutylmethyl, and aryl are preferred.
- R 2 and R 3 are each preferably hydrogen, hydroxy, methoxy, ethoxy, allyloxy, benzyloxy, acetoxy or propionoxy, and preferably hydrogen, hydroxy, methoxy and acetoxy.
- k is preferably an integer of 2 to 8, more preferably 2 to 6, particularly 2 or 6.
- R 5 is alkyl having 1 to 5 carbon atoms, alkylidene having 1 to 5 carbon atoms, cycloalkyl alkyl having 7 to 13 carbon atoms, aralkyl having 7 to 13 carbon atoms, or aralkyl having 7 to 13 carbon atoms.
- Cyclodene or benzo, pyrido, naphtho, cyclopropano, cyclobutanoic cyclopentano, cyclopenteno substituted with two R 5 groups, each substituted on the adjacent carbon, either unsubstituted or substituted with one or more substituents R 6 Forming cyclohexene-containing cyclohexene-containing cycloheptano, or cyclohepteno, and in addition, when X is -S-CH CH-, 4 of the 5 R 5 bonded to the sulfur atom It is preferable that R 5 force ⁇ oxygen atoms become a sulfone group.
- R 1Q hydrogen, alkyl having 1 to 5 carbon atoms, aryl, and benzyl are preferable, and hydrogen and methyl are particularly preferable.
- R u and R 12 are preferably those bonded to -0-, or R 11 is hydrogen, and R 12 is preferably hydrogen, hydroxy, or methoxy. -0- is preferred.
- Pharmacologically preferred acid addition salts include inorganic acid salts such as hydrochloride, sulfate, nitrate, hydrobromide, hydroiodide, phosphate, acetate, lactate, and ken Acid, oxalate, glutarate, malate, tartrate, fumarate, mandelate, maleate, benzoate, organic carboxylate such as phthalate, methanesulfonate Organic sulfonates such as ethane sulfonate, benzene sulfonate, p-toluene sulfonate, camphor sulfonate, etc., among which hydrochloride, hydrobromide, phosphate, tartaric acid salt The power for which methanesulfonate is preferably used is not limited to these.
- R 5 together form an unsubstituted or more than one substituent R 6 substituted benzo or cyclohexeno
- R 1Q , R 13 , R ′′ are hydrogen
- R U , R 12 is bonded to —O—, respectively (la), (la ′)
- —X— is —S—CH ⁇ CH 2 —
- Y is a valence bond, and is bonded to a sulfur atom.
- R 5 force ⁇ number of forms the oxygen atom with a connexion sulfone group, also substituted with adjacent substituents R 6 are two R 5 replacing each carbon together such connection above unsubstituted or one to Specific examples of the compound represented by the general formula (la ") in which R 10 , R 13 , R" are hydrogen, R U , R 12 are bonded to each other are-0- are shown in Table 1. In the table below, CPM is cyclopropylmethyl.
- Numbers assigned to the substituents R 6 are on the benzene ring of the phthalimide structure, key on Sen ring cycloheteroalkyl tetrahydrophthalimide structure, or 0-substitution positions on the benzene ring of the sulfonic acid imide structure and meaning taste, morphinan Skeletal 6-position bond is ⁇ or ⁇ .
- Valence bond to form a base down zone which is substituted by adjacent substituents R 6 above one such connexion unsubstituted or in together two R 5 replacing each carbon, R 1Q, R 13, R 14
- Table 2 shows specific examples of the compound represented by the following general formula (lb) in which is hydrogen, R u , and R 12 are bonded to each other and is -0-.
- the number given to the substituent R 6 represents the substitution position on the benzene ring of the isoindole structure, and “-” represents unsubstituted.
- the morphinan 6-position bond is or ⁇
- R 13 And R 14 are R 13 ′ and R 14 ′ (R 13 ′ and R 14 ′ are oxo together, or R 13 ′ is hydrogen and R 14 ′ is hydroxy, alkoxy having 1 to 5 carbon atoms, carbon number
- General formula (Id) which represents 1 to 5 alkanoyloxy
- a compound represented by International Publication WO 04/033457 General formula (Ic) obtained by the method shown in European Patent Office published EP1555266) R 5, R 1Q, R U , or R 1 2, k, X, Y oxidizes benzylic morphinan derivative conduct
- EP1555266 It can be manufactured by applying the method.
- a hydroxy group or an oxo group can be directly introduced.
- the step of reducing to the hydroxy group after introducing the hydroxy group, the acid group is introduced into the oxo group. It is also possible to go through a process to do. Depending on the type of substituent, protection and deprotection steps may be added as necessary.
- all the oxidizing agents that can be used for the acidity in the benzyl position are generally applicable.
- a manganese (III) salt such as manganese (III) acetate is used.
- Lead compounds such as lead tetraacetate, organic peroxides such as t-butyl hydroperoxide and benzoyl peroxide, cerium compounds such as cerium nitrate (IV) ammonium (CAN), oxygen, etc.
- cerium (IV) nitrate ammonium is useful because an ⁇ -hydroxy compound can be selectively obtained.
- an oxidizing agent containing an organic acid such as acetic acid
- an alkanoyloxy group such as acetoxy may be efficiently introduced in some cases.
- permanganate such as potassium permanganate
- manganese compounds such as manganese dioxide
- chromium compounds such as chromium oxide and sodium dichromate
- diacid selenium Selenium compounds such as sodium periodate
- quinones such as DDQ
- silver compounds such as silver oxide
- cerium compounds such as cerium nitrate (IV) ammonium (CAN)
- halogens chlorine, bromine
- Iodine oxygen
- hydrogen peroxide and so on for example, permanganate such as potassium permanganate, manganese compounds such as manganese dioxide, chromium compounds such as chromium oxide and sodium dichromate, diacid selenium Selenium compounds such as sodium periodate, quinones such as DDQ, silver compounds such as silver oxide, cerium compounds such as cerium nitrate (IV) ammonium (CAN), halogens (chlorine, bromine) , Iodine), oxygen, hydrogen peroxide and so on.
- reaction conditions such as reaction solvent, reaction temperature, reaction time, substrate concentration, and equivalent ratio of reactants are used.
- a cerium compound such as cerium (IV) nitrate (CAN)
- 4 equivalents of oxidant to the substrate in a mixed solvent system of acetonitrile and water can be obtained at a high yield by reacting at room temperature.
- reducing agents used for reducing a normal carbonyl compound are all applicable.
- Hydride reducing agents such as sodium borohydride and lithium aluminum hydride can be used. Preferably used.
- Reaction conditions such as reaction solvent, reaction temperature, reaction time, substrate concentration, and equivalent ratio of the reactants are appropriately selected depending on the reducing agent used. For example, when sodium borohydride is used, an alcohol system such as methanol is used. The target compound can be obtained in high yield by reacting in a solvent at room temperature. When a hydroxy group is synthesized through an oxo group reduction step, a ⁇ -isomer may be selectively obtained as opposed to direct hydroxylation.
- oxidizing agents usually used for oxidizing a hydroxy compound are applicable.
- Pyridinum chromate (PCC), pyridinium dichromate (PDC), manganese dioxide, DMSO / oxalyl chloride, periodate oxides and the like are preferably used.
- reaction conditions such as the reaction solvent, reaction temperature, reaction time, substrate concentration, and equivalent ratio of the reactants are appropriately selected depending on the oxidizing agent used. For example, when DMSO / oxalyl chloride is used, dichloromethane or the like is used.
- the desired compound can be obtained in a high yield by reacting in a halogen solvent of ⁇ 78 ° C. to 0 ° C.
- Conversion of the hydroxy form to the alkoxy form or alkanoyloxy form can be carried out under ordinary etherification and acylation conditions, and salification is pharmacologically acceptable in water or various organic solvents. Can be obtained by mixing with acid and concentrating to dryness, reprecipitation, recrystallization, etc.
- the morphinan derivative having a nitrogen-containing cyclic substituent represented by the general formula (I) or a pharmaceutically acceptable acid addition salt thereof is effective for the treatment of cough is that guinea pigs are used by using cenoic acid. It can be confirmed by showing an inhibitory action against cough induced in the blood. Fly The inhibitory action against acid-induced cough can be confirmed by the method shown in Examples, but is not necessarily limited to this method.
- the antitussive agent of the present invention exhibits a strong inhibitory action against citrate-induced cough in animal studies, all diseases associated with cough such as common cold (cold syndrome), acute bronchitis, chronic bronchitis Inflammation, bronchiectasis, pneumonia, pulmonary tuberculosis, key lung and key lung tuberculosis, lung cancer, upper respiratory tract inflammation (pharyngitis, laryngitis, nasal catarrh), asthmatic bronchitis, bronchial asthma, infant asthma, (chronic) emphysema, pneumoconiosis (Disease), pulmonary fibrosis, pulmonary abscess, pleurisy, tonsillitis, cough urticaria, whooping cough, etc. I can expect.
- common cold cold
- acute bronchitis chronic bronchitis Inflammation
- bronchiectasis pneumonia
- pulmonary tuberculosis key lung and key lung tuberculos
- the antitussive agent of the present invention can be used for mammals (eg, mouse, rat, wild, muster, usagi, cat, inu, ushi, hidge, monkey, human).
- mammals eg, mouse, rat, wild, muster, usagi, cat, inu, ushi, hidge, monkey, human.
- the compound used in the present invention is one or more substances used alone or for the treatment or prevention of a disease, or for the reduction or suppression of symptoms. Can be administered in combination.
- examples of such substances include non-narcotic antitussives such as ephedrine, clofedanol, cloperastine, dimemorphan, dextromethorphan, tralast, nospower pin, pentoxyberine, benproperin, hominoben, methylephrine.
- the drug may be a free base or a salt thereof itself, and also excipients, stabilizers, preservatives, buffers, solubilizers, emulsifiers, dilutions. Additives such as agents and tonicity agents may be mixed as appropriate.
- the drug can be produced by an ordinary method using these drug carriers as appropriate.
- the dosage form includes oral preparations such as tablets, capsules, granules, powders, syrups, parenterals such as injections, suppositories, liquids, or ointments, creams, patches, etc. I can list them. These compositions can be prepared according to commonly used methods.
- the therapeutic or prophylactic agent for cough of the present invention preferably contains 0.00001 to 90% by weight, more preferably 0.0001 to 70% by weight of the above active ingredient.
- the amount to be used is appropriately selected according to symptoms, age, body weight, administration method, etc.In the case of parenteral preparations such as injections for adults, the amount of active ingredient is 0.1 g to 1 lg daily. 18 to 1 ( ⁇ , 0.1 ⁇ g to lg for topical preparations such as ointments, and can be administered once or in several divided doses.
- a test substance solution, a positive control substance (codine phosphate) solution, or a solvent for administration is administered subcutaneously to a 6-week-old Hartley guinea pig at a dose of 0.1 mL / 100 g.
- the chamber was held in place and set in the measuring device.
- 30 minutes after subcutaneous administration of the test substance a nebulizer switch was inserted, and a 100 mM solution of citrate, a cough inducer, was atomized and sprayed on the face of the guinea pig for 15 minutes (rate: 50 mm / min).
- a minipolygraph was used for recording, and the breathing waveform for 15 minutes was recorded.
- codin phosphate 10 mg / kg, s.
- n 3
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2006800483797A CN101340911B (zh) | 2005-12-21 | 2006-12-15 | 镇咳剂 |
JP2007551062A JP5163127B2 (ja) | 2005-12-21 | 2006-12-15 | 鎮咳剤 |
AU2006328765A AU2006328765B2 (en) | 2005-12-21 | 2006-12-15 | Antitussive agent |
EP06834766A EP1974731B1 (en) | 2005-12-21 | 2006-12-15 | Morphinan derivatives for use as antitussive agents |
CA2634055A CA2634055C (en) | 2005-12-21 | 2006-12-15 | Antitussive agent |
US12/158,100 US8106065B2 (en) | 2005-12-21 | 2006-12-15 | Antitussive agent |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005367825 | 2005-12-21 | ||
JP2005-367825 | 2005-12-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007072749A1 true WO2007072749A1 (ja) | 2007-06-28 |
Family
ID=38188528
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/325023 WO2007072749A1 (ja) | 2005-12-21 | 2006-12-15 | 鎮咳剤 |
Country Status (10)
Country | Link |
---|---|
US (1) | US8106065B2 (ja) |
EP (1) | EP1974731B1 (ja) |
JP (1) | JP5163127B2 (ja) |
KR (1) | KR20080081057A (ja) |
CN (1) | CN101340911B (ja) |
AU (1) | AU2006328765B2 (ja) |
CA (1) | CA2634055C (ja) |
ES (1) | ES2369571T3 (ja) |
TW (1) | TW200733963A (ja) |
WO (1) | WO2007072749A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008143239A1 (ja) | 2007-05-21 | 2008-11-27 | Toray Industries, Inc. | 結晶性微粉化粒子 |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014091298A2 (en) | 2012-12-14 | 2014-06-19 | Purdue Pharma L.P. | Nitrogen containing morphinan derivatives and the use thereof |
ES2631197T3 (es) | 2012-12-14 | 2017-08-29 | Purdue Pharma Lp | Análogos de piridonamorfinano y actividad biológica sobre los receptores opiodes |
US8946255B2 (en) | 2012-12-28 | 2015-02-03 | Purdue Pharma L.P. | Substituted morphinans and the use thereof |
TW201441198A (zh) | 2012-12-28 | 2014-11-01 | Purdue Pharma Lp | 7,8-環嗎啡喃類似物 |
US9340542B2 (en) | 2013-12-26 | 2016-05-17 | Purdue Pharma L.P. | Propellane-based compounds and the use thereof |
CA3075740A1 (en) | 2017-09-12 | 2019-03-21 | Yang Ye | Solid forms of stemospironine and its salts |
EP3761982A4 (en) | 2018-03-08 | 2021-12-15 | Victoria Link Ltd | TREATMENT OF DEMYELINIZATION DISEASES |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995003308A1 (en) * | 1993-07-23 | 1995-02-02 | Toray Industries, Inc. | Morphinan derivative and medicinal use |
WO1998023290A1 (fr) * | 1996-11-25 | 1998-06-04 | Toray Industries, Inc. | Agent antiprurigineux |
WO2005094826A1 (ja) * | 2004-03-30 | 2005-10-13 | Toray Industries, Inc. | 止痒剤 |
WO2006049248A1 (ja) * | 2004-11-04 | 2006-05-11 | Toray Industries, Inc. | 鎮痛剤 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3108041A (en) * | 1960-05-11 | 1963-10-22 | Endo Lab | Antitussive compositions |
JPS4118823B1 (ja) * | 1964-02-03 | 1966-10-31 | ||
BR0314754A (pt) * | 2002-10-09 | 2005-07-26 | Toray Industries | Agente terapêutico ou profilático para a frequência urinária ou a incontinência urinária ou um seu sal de adição de ácido farmaceuticamente aceitável, método para terapia ou profilaxia para frequência urinária, urgência urinária ou incontinência urinária, uso de um derivado de morfina tendo um grupo heterocìclico contendo nitrogênio ou de um seu sal de adição de ácido farmaceuticamente aceitável, derivado de morfina ou um seu sal de adição de ácido farmaceuticamente aceitável, produto farmacêutico, e, composição farmacêutica |
-
2006
- 2006-12-15 CA CA2634055A patent/CA2634055C/en not_active Expired - Fee Related
- 2006-12-15 EP EP06834766A patent/EP1974731B1/en not_active Not-in-force
- 2006-12-15 WO PCT/JP2006/325023 patent/WO2007072749A1/ja active Application Filing
- 2006-12-15 AU AU2006328765A patent/AU2006328765B2/en not_active Ceased
- 2006-12-15 CN CN2006800483797A patent/CN101340911B/zh not_active Expired - Fee Related
- 2006-12-15 JP JP2007551062A patent/JP5163127B2/ja not_active Expired - Fee Related
- 2006-12-15 US US12/158,100 patent/US8106065B2/en not_active Expired - Fee Related
- 2006-12-15 ES ES06834766T patent/ES2369571T3/es active Active
- 2006-12-15 KR KR1020087017850A patent/KR20080081057A/ko active IP Right Grant
- 2006-12-19 TW TW095147632A patent/TW200733963A/zh unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995003308A1 (en) * | 1993-07-23 | 1995-02-02 | Toray Industries, Inc. | Morphinan derivative and medicinal use |
WO1998023290A1 (fr) * | 1996-11-25 | 1998-06-04 | Toray Industries, Inc. | Agent antiprurigineux |
WO2005094826A1 (ja) * | 2004-03-30 | 2005-10-13 | Toray Industries, Inc. | 止痒剤 |
WO2006049248A1 (ja) * | 2004-11-04 | 2006-05-11 | Toray Industries, Inc. | 鎮痛剤 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008143239A1 (ja) | 2007-05-21 | 2008-11-27 | Toray Industries, Inc. | 結晶性微粉化粒子 |
US8198446B2 (en) | 2007-05-21 | 2012-06-12 | Toray Industries, Inc. | Crystalline micropowder particles |
Also Published As
Publication number | Publication date |
---|---|
KR20080081057A (ko) | 2008-09-05 |
US8106065B2 (en) | 2012-01-31 |
AU2006328765A1 (en) | 2007-06-28 |
CN101340911A (zh) | 2009-01-07 |
CA2634055A1 (en) | 2007-06-28 |
CN101340911B (zh) | 2013-01-02 |
EP1974731A4 (en) | 2009-05-20 |
CA2634055C (en) | 2011-07-05 |
JP5163127B2 (ja) | 2013-03-13 |
ES2369571T3 (es) | 2011-12-02 |
TW200733963A (en) | 2007-09-16 |
AU2006328765B2 (en) | 2012-01-12 |
US20090176818A1 (en) | 2009-07-09 |
EP1974731A1 (en) | 2008-10-01 |
EP1974731B1 (en) | 2011-07-13 |
JPWO2007072749A1 (ja) | 2009-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007072749A1 (ja) | 鎮咳剤 | |
KR101589846B1 (ko) | 히드로모르폰의 벤조산, 벤조산 유도체 및 헤테로아릴 카르복실산 컨쥬게이트, 전구약물, 이의 제조 방법 및 용도 | |
EP1603597B1 (en) | Oxycodone conjugates with lower abuse potential and extended duration of action | |
TWI275591B (en) | Opiod and opioid-like coumpounds and uses thereof | |
EP1736157B1 (en) | Morphinan derivatives as anti-itching agent | |
KR101285645B1 (ko) | 진통제 | |
TWI501969B (zh) | 丁基原啡因衍生物及其用途 | |
CN102711759B (zh) | 胆道疾病的治疗或预防药 | |
KR20160089516A (ko) | 에테르 측쇄를 함유한 n-치환 이미다졸 카르복실산 에스테르 키랄 화합물, 제조 방법 및 용도 | |
ES2464593T3 (es) | Agente terapéutico o profiláctico para trastornos funcionales digestivos | |
WO2020237747A1 (zh) | 一种长效化合物在制备药物中的应用 | |
ES2307025T3 (es) | Combinacion de opioides y un derivado de la piperazina para el tratamiento del dolor. | |
WO2001005795A1 (fr) | Moyens de traitement et de prevention contre la miction frequente et l'incontinence d'urine | |
US20230111856A1 (en) | Opioid receptor antagonists | |
CN107019803B (zh) | 具有低成瘾作用的聚乙二醇化阿片样物质 | |
CN116082302A (zh) | 氘代吲唑-吡啶-苯基-三氟乙基四取代烯烃类化合物及其用途 | |
KR810001913B1 (ko) | 3-페녹시 n-치환된 모르피난 유도체의 제조방법 | |
JP2003327534A (ja) | 頻尿若しくは尿失禁の治療又は予防剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680048379.7 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007551062 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2634055 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12158100 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006328765 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006834766 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020087017850 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2006328765 Country of ref document: AU Date of ref document: 20061215 Kind code of ref document: A |